secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001213900-22-068745
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q3 net loss $7.7M; FDA clinical hold on XPro AD trials ongoing
-------------------------------------------------------------------------

- Net loss Q3 2022 ~$7.7M vs $9.5M Q3 2021; R&D $5.2M, G&A $2.4M.
- Cash & equivalents ~$57.4M at Sept 30, 2022; ~17.9M shares outstanding.
- FDA clinical hold on XPro1595 AD trials; company addressed CMC query; discussions ongoing.
- INKmune shows positive solid tumor data; 2nd UK site Nov 2022; pre-IND with FDA for solid tumor.
- Upcoming: XPro Phase 2 AD/TRD after hold lifted; INKmune solid tumor 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/0001213900-22-068745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/ea167968-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-068745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer